MUC1 and adenocarcinoma: Combining MUC1 and/or MUC4 expression at these levels (MUC1 > 40% and/or MUC4 > 0%, versus MUC1 < 40% and MUC4 = 0%) indicated a clear survival disadvantage for patients with pancreatobiliary differentiated adenocarcinomas (Figure 5C, P = 0.009).